Celera Neuro pharma launches new product on 5 March 2022 in Namma BENGALURU

 Celera Neuro pharma launches new product on 5 March 2022 in Namma BENGALURU 

 

Apomorphine Therapy 

from EVER Pharma of Germany 

 

at the hands of  

Dr. K Sudhakar 

Hon’ble Minister of Medical Education and Health, Govt. of Karnataka 

at the Academic Symposium on Parkinson's Disease held by King's College London (KCL) and Parkinson's Research Alliance of India (PRAI) in Namma Bengaluru 

 

• This is for the first time that third generation apomorphine pens and pumps, widely used in Western countries, are being launched in India for Parkinson’s patients 
• These pens and pumps were hitherto available in India only on a case-to-case, compassionate basis. They are now being launched commercially after approval of the DCGI, Govt. of India 
• Apomorphine therapy is meant for Parkinson’s patients with advanced disease who are unable to achieve optimum results with available drugs, or those suffering from side-effects of oral medications 
• For years, Parkinson’s patients in India had only two therapeutic options available: traditional oral treatment or the very expensive Deep Brain Stimulation (DBS) surgery 
• The D-mine apomorphine pens and pumps from EVER Pharma now offer a third treatment option. International guidelines today recommend use of apomorphine therapy before even considering DBS for Parkinson’s patients 
• For more info/details,please visit/peruse
• https://www.celeraneuropharma.com
• https://www.celeraneuropharma.in